Key result
Drug-eluting stent implantation in unprotected left main bifurcation lesions resulted in a 1-year cardiac death rate of 4.3% and a per lesion restenosis rate of 13.4%.
Why the study?
What are the long-term outcomes following drug-eluting stent implantation in patients with unprotected left main bifurcation lesions?
Cohort (n=70)
What are the long-term outcomes following drug-eluting stent implantation in patients with unprotected left main bifurcation lesions?
Treatment of unprotected left main bifurcation lesions with drug-eluting stents is feasible with low 1-year mortality, though the 17.1% need for target lesion revascularization highlights room for improvement.
Answers are grounded in this paper and cite their sources.
Supports short-term feasibility of DES for unprotected LM bifurcation; leaves open long-term durability and randomized comparisons.
BACKGROUND: The safety and efficacy of drug-eluting stents (DES) implantation in unprotected left main (LM) bifurcation lesions has yet to be determined. The aim of the present report was to evaluate the long-term outcome following implantation of DES in unprotected LM bifurcation lesions. METHODS: We identified 70 consecutive patients treated with DES in unprotected LM bifurcation lesions from April 2003 to January 2005. Of them, 42 patients were treated with sirolimus-eluting stent (SES) and 28 patients were treated with paclitaxel-eluting stent (PES). RESULTS: Stents to the left anterior descending and to the circumflex were implanted in 62 patients. During 1-year follow-up, 3 (4.3%) patients died of cardiac causes. One of them had myocardial infarction and adjudicated as possibly due to stent thrombosis. Angiographic follow-up was available in 80% of patients. The per lesion restenosis rate was 13.4% in the entire cohort, of which 10.7% occurred in lesions treated with SES and 16.1% in those treated with PES (P = 0.58). All restenosis was focal and occurred in the lesions treated with a stent with stent size to post-procedural reference vessel diameter ratio < 1.0 (17.6% vs 0, P = 0.04). The per patient target lesion revascularization rate at 1 year was 17.1%. One year survival free from major adverse cardiac events was 77.1%. CONCLUSIONS: Treatment of LM bifurcation lesions using DES is a safe and feasible way with a low one-year mortality. The need for revascularization in 17% of patients demands for improvement.
No takes yet. Share an insight, caveat, or question.
Ge et al. (2007) conducted a cohort in unprotected left main bifurcation lesions (n=70). Drug-eluting stents (sirolimus-eluting or paclitaxel-eluting) vs. Sirolimus-eluting vs Paclitaxel-eluting stents was evaluated on per lesion restenosis rate (p=0.58). Drug-eluting stent implantation in unprotected left main bifurcation lesions resulted in a 1-year cardiac death rate of 4.3% and a per lesion restenosis rate of 13.4%.
Synapse has enriched 10 related papers. Consider them for comparative context: